^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma

Excerpt:
This study aimed to examine the role of CD44 in sunitinib resistance and as a predictive marker in mRCC….CD44 expression in mRCC patients treated with first-line sunitinib was determined by immunohistochemistry. We validated the findings of this study by in silico analysis....CD44-positive cases were associated with poor progression-free survival (PFS) after first-line sunitinib treatment.
DOI:
10.21873/anticanres.15301